Claims for Patent: 8,993,727

Summary for Patent: 8,993,727

Title:	Carrier immunoglobulins and uses thereof
Abstract:	Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
Inventor(s):	Walker; Kenneth W. (Newbury Park, CA), Jacobsen; Frederick W. (Newbury Park, CA), Arora; Taruna (Thousand Oaks, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	13/825,547
Patent Claims:	1. An isolated immunoglobulin, comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein: the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:323 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:188. 2. The isolated immunoglobulin of claim 1, wherein the isolated immunoglobulin comprises an antibody or antibody fragment. 3. The isolated immunoglobulin of claim 2, comprising an IgG1, IgG2, IgG3 or IgG4. 4. The isolated immunoglobulin of claim 2, comprising a monoclonal antibody. 5. The isolated immunoglobulin of claim 4, comprising a human antibody. 6. The isolated immunoglobulin of claim 5, comprising: an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:113, or comprising the foregoing sequence from which one, two, three, four or five amino acid residues are lacking from the N-terminal or C-terminal, or both; and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:110, or comprising the foregoing sequence from which one, two, three, four or five amino acid residues are lacking from the N-terminal or C-terminal, or both. 7. The isolated immunoglobulin of claim 1, further comprising at least one pharmacologically active chemical moieties conjugated thereto. 8. The isolated immunoglobulin of claim 7, wherein the pharmacologically active chemical moiety is a pharmacologically active polypeptide. 9. The isolated immunoglobulin of claim 8, wherein the immunoglobulin is recombinantly produced. 10. The isolated immunoglobulin of claim 9, wherein the immunoglobulin comprises at least one immunoglobulin heavy chain and at least one immunoglobulin light chain, and wherein the pharmacologically active polypeptide is inserted in the primary amino acid sequence of the of the immunoglobulin heavy chain within an internal loop of the Fc domain of the immunoglobulin heavy chain. 11. The isolated immunoglobulin of claim 8, wherein the immunoglobulin comprises at least one immunoglobulin heavy chain and at least one immunoglobulin light chain, and wherein the pharmacologically active polypeptide is conjugated at the N-terminal or C-terminal of the immunoglobulin heavy chain. 12. The isolated immunoglobulin of claim 8, wherein the immunoglobulin comprises at least one immunoglobulin heavy chain and at least one immunoglobulin light chain, and wherein the pharmacologically active polypeptide is conjugated at the N-terminal or C-terminal of the immunoglobulin light chain. 13. The isolated immunoglobulin of claim 8, wherein the pharmacologically active polypeptide is a toxin peptide, an IL-6 binding peptide, a calcitonin gene related peptide (CGRP) peptide antagonist, a bradykinin B1 receptor peptide antagonist, a parathyroid hormone (PTH) agonist peptide, a PTH antagonist peptide, an angiopoietin-1 (ang-1) binding peptide, an angiopoietin-2 (ang-2) binding peptide, a myostatin binding peptide, an erythropoietin (EPO)-mimetic peptide, a fibroblast growth factor 21 (FGF21) peptide, a thombopoietin (TPO)-mimetic peptide, a nerve growth factor (NGF) binding peptide, a B-cell activating factor (BAFF) antagonist peptide, a glucagon-like peptide-1 (GLP-1) or peptide mimetic thereof, or a glucagon-like peptide-2 (GLP-2) or peptide mimetic thereof. 14. The isolated immunoglobulin of claim 13, wherein the toxin peptide is stichodactyla toxin (ShK) or a ShK peptide analog. 15. A pharmaceutical composition comprising the immunoglobulin of claim 1; and a pharmaceutically acceptable diluent, excipient or carrier. 16. The immunoglobulin of claim 1, wherein the immunoglobulin at 30 micromolar concentration does not significantly bind soluble human IL-17R (SEQ ID NO:89) at 30 nanomolar concentration in an aqueous solution incubated under physiological conditions, as measured by a surface plasmon resonance binding assay.

Details for Patent 8,993,727

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2030-09-22